Stay Versus Stay: How Litigation Stays Pending IPRs Impact the 30-Month Regulatory Stay in Hatch-Waxman Litigation

Stay Versus Stay: How Litigation Stays Pending IPRs Impact the 30-Month Regulatory Stay in Hatch-Waxman Litigation

Publication

Related Documents

Related Solutions

Providing comprehensive solutions for the acquisition, enforcement and protection of IP.
Clients trust us to protect their most important intellectual property matters.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
We advise clients on the smartest, most cost-effective ways to challenge or defend issued patents.

In this article published in BNA's Patent, Trademark and Copyright Journal, Andrea Weiss Jeffries and Nancy Schroeder detail the impact of the Hatch-Waxman Act on pharmaceutical companies and patent infringement actions.

Upon initiation of a patent infringement action between branded and generic pharmaceutical companies, the Hatch-Waxman Act (21 U.S.C. § 355(j)) provides for an automatic 30-month stay of Food and Drug Administration approval of the Abbreviated New Drug Application (ANDA) for the proposed generic pharmaceutical product. Read the full article

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel